NASDAQ:SCYX SCYNEXIS (SCYX) Stock Price, News & Analysis $1.76 -0.02 (-1.12%) (As of 10:47 AM ET) Add Compare Share Share Today's Range$1.75▼$1.7850-Day Range$1.65▼$2.2352-Week Range$1.35▼$3.87Volume12,828 shsAverage Volume198,150 shsMarket Capitalization$66.63 millionP/E Ratio0.86Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get SCYNEXIS alerts: Email Address Ad Crypto 101 MediaThis Crypto Is Set to Explode in AugustWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make HUGE gains. Industry Giants are Investing Heavily in Blockchain Technology and THIS COIN is at the Heart of Their Strategy. It's a groundbreaking opportunity that could be poised for extraordinary gains. Go here to get full details on this crypto now. About SCYNEXIS Stock (NASDAQ:SCYX)SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.Read More SCYX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SCYX Stock News HeadlinesAugust 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for SCYNEXIS Amid Antifungal Progress and Market PotentialAugust 13, 2024 | americanbankingnews.comSCYNEXIS (NASDAQ:SCYX) Downgraded by StockNews.com to SellAugust 22, 2024 | Darwin (Ad)2024's Must-Watch Stocks!Welcome to a year of unparalleled opportunities! Dive into our exclusive guide, "9 Stocks Set to Soar," meticulously selected to elevate your portfolio in 2024. Step into 2024 with confidence and the right assets at your fingertips. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time. August 9, 2024 | au.finance.yahoo.comSCYNEXIS, Inc. (SCYX) stock historical prices & data – Yahoo FinanceAugust 9, 2024 | markets.businessinsider.comSCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 9, 2024 | investorplace.comSCYX Stock Earnings: SCYNEXIS Misses EPS, Misses Revenue for Q2 2024August 8, 2024 | globenewswire.comSCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateJuly 25, 2024 | money.usnews.comScynexis IncAugust 22, 2024 | Crypto 101 Media (Ad)Massive Crypto Selloff = Historic OpportunityStocks recently suffered the worst 1-day loss since 2022… Cryptos got hammered as well…But here's the fact everyone is missing… As of this writing, Bitcoin is still up 28% year to date…And it's up 84% in the last year. July 23, 2024 | globenewswire.comSCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study ReportsJuly 22, 2024 | investorplace.com3 Stocks Under $10 With the Potential for Massive GainsJuly 22, 2024 | investorplace.com3 Stocks Under $10 With the Potential for Massive GainsJuly 11, 2024 | investorplace.com3 Dirt-Cheap Drug Developers With Blockbuster PotentialJuly 1, 2024 | investorplace.com7 Undervalued Biotech Stocks to Buy for Big-Time ReturnsMay 31, 2024 | investorplace.comHidden Gems: 3 Under-$10 Stocks Poised for 500% Growth by 2025May 23, 2024 | investorplace.com3 Stocks Under $10 With Mammoth Growth ProspectsMay 10, 2024 | markets.businessinsider.comBuy Recommendation: Scynexis’s Ibrexafungerp Promises Market Breakthrough and Financial GrowthMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Scynexis on Robust Financials and Promising Antifungal PipelineSee More Headlines Receive SCYX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SCYNEXIS and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today8/22/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SCYX CUSIPN/A CIK1178253 Webwww.scynexis.com Phone(201) 884-5485Fax201-884-5490Employees60Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$2.04 Trailing P/E Ratio0.87 Forward P/E RatioN/A P/E GrowthN/ANet Income$67.04 million Net Margins-366.09% Pretax Margin-359.17% Return on Equity-57.41% Return on Assets-34.18% Debt Debt-to-Equity RatioN/A Current Ratio3.75 Quick Ratio3.75 Sales & Book Value Annual Sales$140.14 million Price / Sales0.48 Cash Flow$1.96 per share Price / Cash Flow0.91 Book Value$1.96 per share Price / Book0.91Miscellaneous Outstanding Shares37,860,000Free Float36,703,000Market Cap$67.43 million OptionableOptionable Beta1.52 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. David Gonzalez Angulo M.D. (Age 59)CEO, President & Director Comp: $868.03kMr. Ivor Macleod CPA (Age 63)M.B.A., Chief Financial Officer Comp: $626.9kMr. Scott Sukenick J.D. (Age 46)Chief Legal Officer & Corporate Secretary Comp: $623.7kMs. Daniella GiganteVice President of Human Resources & Information TechnologyKey CompetitorsEntasis TherapeuticsNASDAQ:ETTXEnanta PharmaceuticalsNASDAQ:ENTACartesian TherapeuticsNASDAQ:RNACCorvus PharmaceuticalsNASDAQ:CRVSAmarinNASDAQ:AMRNView All CompetitorsInstitutional OwnershipRenaissance Technologies LLCSold 217,240 shares on 8/9/2024Ownership: 0.368%Acadian Asset Management LLCBought 119,600 shares on 8/6/2024Ownership: 1.431%View All Institutional Transactions SCYX Stock Analysis - Frequently Asked Questions How have SCYX shares performed this year? SCYNEXIS's stock was trading at $2.23 at the beginning of 2024. Since then, SCYX shares have decreased by 20.2% and is now trading at $1.78. View the best growth stocks for 2024 here. How were SCYNEXIS's earnings last quarter? SCYNEXIS, Inc. (NASDAQ:SCYX) released its quarterly earnings results on Thursday, August, 8th. The company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by $0.11. The business earned $0.74 million during the quarter. SCYNEXIS had a negative net margin of 366.09% and a negative trailing twelve-month return on equity of 57.41%. When did SCYNEXIS's stock split? Shares of SCYNEXIS reverse split before market open on Friday, July 17th 2020. The 1-10 reverse split was announced on Thursday, July 16th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 16th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are SCYNEXIS's major shareholders? Top institutional investors of SCYNEXIS include Acadian Asset Management LLC (1.43%) and Renaissance Technologies LLC (0.37%). Insiders that own company stock include Marco Taglietti and Scott Sukenick. View institutional ownership trends. How do I buy shares of SCYNEXIS? Shares of SCYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of SCYNEXIS own? Based on aggregate information from My MarketBeat watchlists, some other companies that SCYNEXIS investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Sorrento Therapeutics (SRNE), KushCo (KSHB), Zosano Pharma (ZSAN) and Bionano Genomics (BNGO). This page (NASDAQ:SCYX) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored625,000% GainThe recent crypto pullback has been brutal, causing widespread panic among investors. But for us, it’s just an...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SCYNEXIS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SCYNEXIS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
